These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16111472)

  • 1. Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity.
    Jimeno A; Hidalgo M
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):727-35. PubMed ID: 16111472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer.
    Edelman MJ
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S3-8. PubMed ID: 16459173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.
    Adams R; Maughan T
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):503-18. PubMed ID: 17428171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
    Eberhard DA; Giaccone G; Johnson BE;
    J Clin Oncol; 2008 Feb; 26(6):983-94. PubMed ID: 18281673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
    Sangha R; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor inhibitors: current status and future directions.
    Chen HX; Cleck JN; Coelho R; Dancey JE
    Curr Probl Cancer; 2009; 33(4):245-94. PubMed ID: 20082842
    [No Abstract]   [Full Text] [Related]  

  • 7. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology of interactions: antiepidermal growth factor receptor agents.
    Harari PM; Allen GW; Bonner JA
    J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.
    Krause M; Baumann M
    Cancer Metastasis Rev; 2008 Sep; 27(3):387-402. PubMed ID: 18427731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
    Kancha RK; von Bubnoff N; Peschel C; Duyster J
    Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
    Jänne PA
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials referral resource. Current clinical trials of agents targeting epidermal growth factor receptor.
    Dancey JE; Schoenfeldt M
    Oncology (Williston Park); 2003 Jun; 17(6):819, 826-30, 833-4 passim. PubMed ID: 12846126
    [No Abstract]   [Full Text] [Related]  

  • 15. New agents in development for breast cancer.
    Gao XP; Liu F
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):68-74. PubMed ID: 17218855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting growth factors and angiogenesis; using small molecules in malignancy.
    Wanebo HJ; Argiris A; Bergsland E; Agarwala S; Rugo H
    Cancer Metastasis Rev; 2006 Jun; 25(2):279-92. PubMed ID: 16770540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
    Johnston SR
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.